Acta Dermato-Venereologica (Nov 2020)

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

  • Céline Phan,
  • Nathalie Beneton,
  • Juliette Delaunay,
  • Ziad Reguiai,
  • Claire Boulard,
  • Anne-Claire Fougerousse,
  • Elisa Cinotti,
  • Marco Romanelli,
  • Laure Mery-Bossard,
  • Domitille Thomas-Beaulieu,
  • Josiane Parier,
  • François Maccari,
  • Jean-Luc Perrot,
  • Mireille Ruer-Mulard,
  • Marie Bastien,
  • Edouard Begon,
  • Mahtab Samimi,
  • Caroline Jacobzone,
  • Nathalie Quiles-Tsimaratos,
  • Vincent Descamps,
  • Maud Steff,
  • Paul Bilan,
  • Annie Vermersch-Langlin,
  • Mathilde Kemula,
  • Emmanuelle Amazan,
  • Ingrid Kupfer-Bessaguet,
  • Anne-Caroline Cottencin,
  • Francesca Prignano,
  • Bulai Livideanu,
  • Jeremy Gottlieb,
  • Alain Beauchet,
  • Emmanuel Mahé

DOI
https://doi.org/10.2340/00015555-3678
Journal volume & issue
Vol. 100, no. 18
p. adv00316

Abstract

Read online

Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years.

Keywords